Option Care Health (OPCH) is under legal scrutiny after Kirby McInerney LLP launched an investigation into alleged securities law violations following weaker first quarter 2026 results and a reduced full year revenue outlook.
See our latest analysis for Option Care Health.
The share price reaction has been sharp, with a 1 month share price return down 26.30% and a 3 month share price return down 42.01%, while the 5 year total shareholder return remains positive at 14.12%. This suggests recent momentum has weakened against a longer term gain.
If recent volatility in Option Care Health has you reassessing your exposure to healthcare, it can help to widen your watchlist and review 34 healthcare AI stocks
With the stock down sharply over 1 year and trading at a discount to both an analyst price target and some intrinsic value estimates, the key question is simple: is this a reset that creates opportunity, or is the market already accounting for future growth?
Most Popular Narrative: 31.9% Undervalued
At a last close of $20.93 versus a widely followed fair value of about $30.73, the current price sits well below the narrative valuation, which is built on detailed assumptions about earnings, margins, and future cash flows using a 6.98% discount rate.
Growth in both acute and chronic infusion therapies is outpacing the market, driven by demographic shifts (aging population and higher prevalence of chronic/complex conditions), which is expanding Option Care Health’s addressable market and positioning the company for sustained revenue growth.
Want to see what kind of revenue curve and margin profile would justify that higher fair value? The narrative leans heavily on compounding earnings power, a richer therapy mix, and a future earnings multiple that assumes investors keep paying up for this cash flow profile. Curious which specific growth and profitability levers carry the most weight in that model?
Result: Fair Value of $30.73 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, you also need to weigh risks such as tighter reimbursement terms and a shift toward lower margin therapies, which could challenge the bullish earnings narrative.
Find out about the key risks to this Option Care Health narrative.
Next Steps
With mixed sentiment around Option Care Health, now is a good time to move quickly, review the data, and decide where you stand on its 3 key rewards and 1 important warning sign
Looking for more investment ideas?
Do not stop with one stock. Use this moment to expand your watchlist, compare different types of opportunities, and give yourself more options for your next move.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
